The emergence of numerous variants of SARS-CoV-2, the causative agent of COVID-19, has presented new challenges to the global efforts to control the COVID-19 pandemic. Here, we obtain two cross-neutralizing antibodies (7D6 and 6D6) that target Sarbecoviruses’ receptor-binding domain (RBD) with sub-picomolar affinities and potently neutralize authentic SARS-CoV-2. Crystal structures show that both antibodies bind a cryptic site different from that recognized by existing antibodies and highly conserved across Sarbecovirus isolates. Binding of these two antibodies to the RBD clashes with the adjacent N-terminal domain and disrupts the viral spike. Both antibodies confer good resistance to mutations in the currently circulating SARS-CoV-2 variants. Thus, our results have direct relevance to public health as options for passive antibody therapeutics and even active prophylactics. They can also inform the design of pan-sarbecovirus vaccines.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the ongoing global coronavirus disease 2019 (COVID-19) pandemic, is the third human coronavirus to cause widespread infection1. It has already claimed nearly 4.01 million lives and contributed to over 185.2 million confirmed cases in 219 countries and territories as of 8 July 2021, with broad consequences for public health and global economy1,2,3. Antibodies from convalescent donors have shown efficacy in treating COVID-19 caused by the original virus strain of SARS-CoV-2 (refs. 4,5), and antibody cocktails have been clinically prescribed under Emergency Use Authorization (EUA) to patients, as in a well-publicized case6. More recently, several vaccines that confer excellent COVID-19 protection efficacy have been administrated broadly under EUA or (in some countries) full approval7. However, the emerging SARS-CoV-2 variants escape neutralization by some of the more potent neutralizing antibodies, diminish the effectiveness of the approved vaccines, and reduce the efficacy of existing antibody cocktail treatment8,9,10. For example, the Moderna (mRNA-1273), Pfizer (BNT162b2), and Novavax (NVX-CoV2373) vaccines show lower protection efficacy for these epidemic variants than the original strains2,11. A more broadly protective vaccine that could prevent infection of known and future variants would clearly be preferable, and broadly neutralizing antibodies could be used as both therapeutics and prophylactics12,13. Such antibodies can also be used to identify highly conserved antigenic determinants across various coronavirus strains to guide design of a broad-spectrum vaccine and to serve as indicators for cross-protection potential upon vaccine immunization.
Transmission between individuals is driven by the spike glycoprotein (S) on the viral surface14,15. Each S monomer is proteolytically cleaved into S1 and S2 subunits prior to mediating virus entry into host cells by interacting with surface receptors14,15. Both SARS-CoV-2 and SARS-CoV enter host cells by engaging with the angiotensin-converting enzyme 2 (ACE2) receptor, which is recognized by the receptor-binding domain (RBD) of S15. To bind ACE2, the RBD must shift from a closed to an open conformation, and subsequent shedding of S1 allows the large-scale fusogenic transition of S2 (refs. 14,16,17). Therefore, S protein and host factors related to cell entry of SARS-CoV-2 are promising targets for therapeutics development against COVID-19 (refs. 18,19,20). Among reported potently neutralizing antibodies (nAbs), most neutralize coronaviruses by targeting the receptor-binding motif (RBM) within the RBD to block S from engaging with ACE2 (refs. 5,21,22). However, many of these nAbs are specific to either SARS-CoV-2 or SARS-CoV, and some do not neutralize variant strains8. To date, at least two classes of cross-neutralizing antibodies have been identified, represented by CR3022 (refs. 23,24) and S309 (ref. 25). These nAbs recognize two non-overlapping conserved epitopes distal from the RBM. The neutralization activity of S309 was found to be impaired by mutations in the B.1.1.7 (Alpha) variant8; the neutralizing activity of CR3022 for that variant remains to be determined.
In this study, we raised two cross-neutralizing antibodies, 7D6 and 6D6, by immunization of mice with the SARS-CoV-2 S-trimer alone (7D6) or in combination with the SARS-CoV S-trimer and MERS-CoV RBD (6D6). High-resolution crystal structures reveal that both antibodies target a distinctive cryptic site of the RBD with high conservation. Our results thus help expand the epitope coverage for antibody cocktail therapies for emerging variants, and augment existing strategies for designing pan-sarbecovirus vaccines.
Cross-neutralizing antibodies elicited by combined immunization of coronavirus spikes
To obtain cross-neutralizing antibodies, we explored immune response to combined immunization of Sarbecoviruses. Mice were immunized with SARS-CoV-2 spike protein alone and in combination with the SARS-CoV spike protein and the MERS-CoV RBD26 (Fig. 1a, b). The hybridoma cell pools with reactivities against both SARS-CoV-2 and SARS-CoV spikes were selected and screened for cross-reactive monoclonal antibodies (mAbs). We obtained 5 and 10 lead mAbs from the single and combined immunization strategies, respectively (Fig. 1c and Table S1). Four of the five mAbs derived from the SARS-CoV-2 spike protein immunization recognized the S2 protein, whereas the fifth mAb targeted the RBD. From the combined immunization, only one of ten antibodies recognized the S2 protein, and the remaining nine mAbs recognized S1, eight of which targeted the RBD.
We next evaluated the neutralization potency of these 15 mAbs using the lentiviral virus (LV)27 and vesicular stomatitis virus (VSV) pseudotyping systems28. A total of seven mAbs—one from the SARS-CoV-2 spike protein immunization and six from the Sarbecovirus spike immunization—showed cross-neutralizing activities against SARS-CoV-2 and SARS-CoV. All seven cross-neutralizing mAbs recognized the RBD (Table S1). In terms of the overall profiles of cross-reactivity and cross-neutralization, three mAbs—7D6, 6D6, and 16D8—stood out as lead antibodies and conferred potent cross-neutralization, with IC50 value ranging from 2.56 to 8.91 μg/mL for SARS-CoV-2 pseudotyped LV (LV-SARS-CoV-2), 1.21 to 10.11 μg /mL for LV-SARS-CoV, and 0.04 to 0.26 μg/mL for VSV-SARS-CoV-2 (Fig. 2a–c). By contrast, the cross-neutralizing antibody CR3022 had poor neutralizing activity against LV-SARS-CoV-2 (IC50 > 284 μg/mL) in our assay (Fig. 2a).
Characterization of cross-neutralizing antibodies
We selected the three promising mAbs for further investigation—7D6 (raised by single immunization strategy), and 6D6 and 16D8 (raised by combined strategy)—and evaluated their neutralization activities against authentic SARS-CoV-2 (ref. 5). All three cross-neutralizing mAbs neutralized SARS-CoV-2 with comparable IC50 values: 2.23, 1.77, and 5.30 μg/mL, respectively (Fig. 2d). Using surface plasmon resonance (SPR) analysis, we found that these neutralizing mAbs interacted with the two-proline stabilized S trimer (S-2P) and RBD with nanomolar or subnanomolar affinities, for both SARS-CoV and SARS-CoV-2 strains (Fig. 2e, Fig. S2 and Table S2). In particular, 7D6 bound the RBD with a 2-log higher affinity than the trimeric S-2P, and 6D6, which showed comparable binding affinities to the two proteins, had 2-log higher affinities for SARS-CoV-2 proteins than SARS-CoV proteins (Fig. 2e). 16D8 showed the same RBD-binding preference as did 7D6, but like 6D6, a lower affinity for SARS-CoV proteins than for SARS-CoV-2 proteins. A blocking assay confirmed that 16D8 inhibited binding of ACE2 with the RBD, while 7D6 and 6D6 did not (Fig. 2f). In a competition assay, we found that 6D6 completely blocked 7D6 from binding the RBD (Fig. 2g) and that 16D8 could block neither 7D6 nor 6D6. These results indicate overlap of the 7D6 and 6D6 epitopes and that these epitopes are distinct from the RBM and from the binding sites of most other RBD-directed mAbs as well as from the epitope of 16D8, which probably overlaps the RBM.
Structural basis of 7D6/6D6 cross-neutralization
We characterized the details of binding between these antibodies and SARS-CoV-2 spikes by determining crystal structures of Fab-RBD immune complexes. We obtained crystals of SARS-CoV-2 RBD bound with Fabs of 7D6, 6D6, or 16D8 and determined the structures at 1.40 and 1.92 Å resolutions for RBD:7D6 and RBD:6D6 complexes, respectively (Fig. S1 and Table S3). We showed that 7D6 and 6D6 bind, in similar orientations, to a nearly identical region of the RBD (Fig. 3a, d). Their common epitope is distal to the RBM (Fig. 3g), consistent with the SPR results above (Fig. 2f). The paratopes of 7D6 and 6D6 comprise six and five complementarity determining region (CDR) loops, respectively, with a buried area at the antibody-RBD interface of about 796 Å2 (HCDRs accounting for 73.3%; LCDRs, 26.7%) and 1,019.1 Å2 (HCDRs, 54.7%; LCDRs, 45.3%), respectively (Fig. 3b, e). The epitopes for 7D6 and 6D6 are formed by 21 and 25 residues, respectively, most of which are in the η1, β1, β5, and β7–β8 RBD loops, with 18 shared residues (Fig. 3c, f, i and Fig. S2). Their contacts are conserved in the SARS-CoV-2 variants: 21 (21/21, 100%) conserved residues for binding with 7D6 and 25 (25/25, 100%) conserved residues for 6D6 (Fig. 3i). The 18 shared residues within the epitope are conserved (89.0%) across Sarbecovirus isolates including clade 1, 2, 3 (ref. 29) (Fig. 3h and Table S4); we denote this shared region as the 7D6/6D6 site.
7D6 interacts with the SARS-CoV-2 RBD mainly through eight hydrogen bonds and van der Waals contacts between HCDR1-3 and residues 346–355 and 466–471 of the RBD (Fig. 3j); RBD residues T470, Y351, R346, R466, and R355 are critical for these interactions (Fig. 3k). For 6D6, the binding site comprises predominantly two RBD segments, one from residues 351 through 357 and the other from residues 457 through 471 (Fig. 3l). A strong and extensive interaction network, including 15 hydrogen bonds and several van der Waals contacts, is formed between 6D6 and the RBD, with T470, E471, Y351, R466, F464, R355, P463, R457, N460, E465, and R357 acting as key residues in the antigenic determinant (Fig. 3m). Among the critical residues in the 7D6 and 6D6 epitopes, there are five amino acid variations between SARS-CoV-2 and SARS-CoV (T470 in SARS-CoV-2 to N in SARS-CoV, R346→K, E471→V, N460→K, R357→K), but these differences do not substantially affect cross-reactivity (Fig. 2a, b).
Mutation resistance of 7D6/6D6 and classification of SARS-CoV-2 RBD nAbs
Over the past year, antibody resistance has developed in SARS-CoV-2 variants, including B.1.1.7 (Alpha) and B.1.351 (Beta)8. Mutations in the RBM include N501Y in the B.1.17 variant, K417N/E484K/N501Y in the B.1.351 variant, K417T/E484K/N501Y in the P.1 (Gamma) variant, L452R/T478K in the B.1.617.2 (Delta) variant, L452R/E484Q in the B.1.617.1 (Kappa) variant, E484K in the B.1.526 (Iota) variant, and L452Q/F490S in the C.37 (Lambda) variant30. All these positions are outside the 7D6/6D6 site (Fig. 4a), and 7D6 and 6D6 maintain, as expected, strong reactivities for the RBD in proteins bearing these typical mutations (Fig. 4b). In contrast, COVID-19 convalescent sera had lower reactivities to RBD mutants, although to varying extents. Moreover, 7D6 and 6D6 showed nearly unchanged neutralizing potency against LV-SARS-CoV-2 of the circulating B.1.1.7, B.1.351, P.1 variants, and as well as against the B.1.351 authentic virus. Control REGN10933 had significantly lower activity against LV-SARS-CoV-2 of B.1.351 and P.1, and unchanged activity against B.1.1.7 (Fig. 4b and Figs. S3–S4).
A global competition analysis of RBD antibodies31 has allowed the RBD-targeting nAbs to be grouped into three classes (Class 1–3) (Fig. 4c). Class 1 includes antibody S309 (ref. 25), which has a footprint distinct from the RBM and from the CR3022 epitope. The 7D6/6D6 site is also away from the RBM, proximal to the S09 epitope but non-overlapping. We therefore group 7D6 and 6D6 into Class 1, and suggest that they may have properties distinct from those of S309 because they appear to destabilize the trimeric spike (Fig. 4c, d and Table S5). Antibodies in Class 2 are SARS-CoV-2 specific, as represented by antibody CB6 and others4,5,21,22,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51. The epitopes for antibodies in Class 2 overlap to varying extent with the ACE2 binding site and likely neutralize the virus by blocking ACE2 from binding to the RBD. Class 3 has a total of eight antibodies including four cross-neutralizing ones23,39,51,52,53,54,55; CR3022, which falls in this class, targets a cryptic epitope on the outer side of the RBD and may cause neutralization by antibody-induced spike disruption24. Antibodies in Classes 1 and 3 bind two separate regions distal to the RBM. For COVID-19 therapy, passive treatment with individual antibodies or with non-competing antibody cocktails is an effective approach; three antibodies or combinations have been approved under Emergency Use Authorization (EUA) (Fig. 4e), although these have somewhat lower efficacy for the emerging variants8,9,10. Thus, 7D6 and 6D6 bind a conserved site distinct from these other clinical antibodies (Fig. 4e), and their appropriate humanized forms could be potential candidate therapeutics, or enhancers to existing cocktails, to protect against variants.
Mechanism of 7D6/6D6-mediated neutralization
We docked the two immune-complex structures into the structure of the trimeric spike, superposing the RBD in either its open or closed conformation. In all interaction scenarios, the bound Fabs would clash with the adjacent NTDs (Fig. 5a, b, e, f, i, j, m, n). The overlapping volumes of 7D6 to the adjacent NTD in the models were 3,700 A3 for RBD up and 11,800 A3 for RBD down, and the occluded volumes for 6D6 were 3,700 A3 (RBD up) and 13,100 A3 (RBD down) (Fig. 5c, g, k, o). Therefore, the 7D6/6D6 site, located on the inner aspect of the RBD facing the adjacent NTD, is cryptic in the context of the entire trimeric spike (Fig. 5d, h, l, p).
We then examined binding of 7D6 or 6D6 to S-2P in vitro. High-performance liquid chromatography (HPLC) analysis showed that S-2P incubated with 7D6 or 6D6 Fab dissociates into smaller components (Fig. 6a, b). Cryo-electron microscopy imaging of S-2P in complex with 7D6 or 6D6 Fab and 2D classification analyses of the resulting complexes confirmed antibody-mediated disruption of the trimeric spike (Fig. 6c). We then carried out the shedding assay using the full-length wild type S (S-WT) expressed on the surface of 293T cells and quantified the results by flow cytometry. Both full-length and Fab forms of antibodies7D6 and 6D6 triggered spike shedding of up to 63% after incubating with cells for 120 min, more potently than control CR3022 (Fig. 6d). These results confirm our proposed neutralization mechanism for 7D6/6D6 by antibody-induced spike shedding (Fig. 6e).
The mechanism of neutralization by the SARS-CoV-2 cross-neutralizing antibody CR3022 is by antibody-induced spike disruption24. We likewise showed previously that the 8C11 antibody can neutralize native hepatitis E virus (HEV) by antibody-imposed physical disruption56. Although the 7D6/6D6 site is inaccessible for antibody binding to the trimeric spike, 7D6 and 6D6 still associate with the S-2P protein with good affinities (Fig. 2e), suggesting that the RBD might have a range of orientations with respect to the NTD, allowing the antibody to bind upon transient exposure of the 7D6/6D6 site. That is, the cryptic 7D6/6D6 site may be exposed transiently by inter-domain movement, as found for the hemagglutinin of the influenza virus57,58. Despite the similar binding orientations and footprints of the two antibodies, 7D6 has higher affinity for the RBD than for S2P, while the corresponding affinities for 6D6 are comparable (Fig. 2e), perhaps because the epitope of 7D6 is more inaccessible in the structural context of S trimer than that of 6D6 (Fig. 5c, g, k, o). We propose 7D6/6D6 might neutralize virus by S1 shedding (Fig. 6e), as supported by antibody-induced spike shedding in vitro (Fig. 6d).
Several COVID-19 vaccines are already available and in use, and over 200 candidates are under development, mostly using the spike protein sequence from the original SARS-CoV-2 strain7. This study demonstrates that combined immunization with multiple Sarbecoviruses spikes can produce more cross-neutralizing antibodies than immunization with SARS-CoV-2 spike only. Vaccination regimens with a combined and/or sequential immunization strategy might provide cross-immunity for SARS-CoV-2 and SARS-CoV as well as for circulating variants by focusing the response on cross-neutralizing epitopes such as the conserved 7D6/6D6 site. The potential for affinity maturation in the development of human B cell memory during long-term immunization might be part of such an approach. Furthermore, the combined immunization strategy suggests that cross-neutralizing antibody might be readily produced by vaccination of convalescent COVID-19 patients who have recovered from infection by the original SARS-CoV-2 or some of its variants. The more potent cross-neutralizing antibodies might be isolated from those convalescent individuals and used to improve the efficacy and mutation resistance of therapeutic antibodies or cocktails against current and future variants.
A wide-spectrum vaccine is an appealing way to establish broad immunity and good tolerance against emerging variants. Identification of conserved sites and understanding antibody-mediated neutralization mechanisms are essential for design of broadly protective vaccines56,57,59. Although 7D6 and 6D6 recognize conserved epitopes on the RBD distinct from those bound by most broadly protective antibodies and are relatively insensitive to the mutations (from the common, G614 parent strains) in the B.1.17, P.1, and B.1.351 variants, the 7D6 and 6D6 antibodies themselves would require further modifications—such as mouse-human chimeric grafting, humanized engineering and affinity maturation—to be candidates for clinical application. Their protective efficacy in vivo will also need to be verified. How best to expose the cryptic 7D6/6D6 site in immunogen design will likewise be required before contemplating any pre-clinical trials.
In summary, we have elicited SARS-CoV-2 cross-neutralizing antibodies in mice by a combined immunization strategy and shown that two cross-neutralizing antibodies, 7D6 and 6D6, bind tightly to the RBD and cross-neutralize SARS-CoV-2 and SARS-CoV by targeting a conserved cryptic site on the RBD. These two antibodies interfere with the neighboring NTD and appear to favor dissociation of S1 from the spike complex. The insensitivity of 7D6/6D6 to the mutations found in the RBDs of currently circulating SARS-CoV-2 variants suggests that 7D6 and 6D6 merit consideration as candidate therapeutic antibodies. The antigenic region described here is also a good target for rational design of pan-sarbecovirus vaccines.
All procedures in this study involving the authentic COVID-19 virus were performed in a biosafety level 3 (BSL-3) facility of the Shenzhen Third People’s Hospital, China. The experimental protocols were approved by the Xiamen University Laboratory Animal Management Ethics Committee. All manipulations were strictly conducted in compliance with animal ethics guidelines and approved protocols.
Cell lines used in this study were obtained from the ATCC (H1299, BHK21, 293T, and Vero E6) or Thermo Fisher Scientific Inc. (CHO, sf9, and High Five cells). All cell lines used in this study were routinely tested for mycoplasma and found to be mycoplasma-free.
Cloning, protein expression and purification of Sarbecovirus S-related proteins
The SARS-CoV-2, SARS-CoV, MERS-CoV S-2P proteins, and/or RBDs were prepared as previously described26. In brief, the S genes (from the sequences of Genbank accession nos. NC_045512.2, NC_004718.3, and AFY13307.1 corresponding to SARS-CoV-2, SARS-CoV, and MERS-CoV, respectively) were synthesized and individually cloned into a baculovirus shuttle vector pAcgp67B (BD Biosciences, CA, USA) using Gibson assembly. The expression and purification of S-2P and RBD constructs were performed as described previously26. Hive Five cells (BTI-TN-5B1-4) (Thermo Fisher Scientific) were cultured in ESF921 medium (Expression Systems) and infected with recombinant virus at a multiplicity of infection (MOI) of 5 in the exponential growth phase (2 × 106 cells/mL; 95% viability) at 28 °C for 72 h. The culture media was centrifugated at 7000g for 20 min. The supernatant was dialyzed against phosphate-buffered saline (PBS), pH 7.4, purified with Ni-sepharose fast-flow 6 resin (GE Healthcare, Boston, USA), and eluted with 250 mM imidazole. The protein concentrations of the final purified samples were measured with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). The SARS-CoV-2 RBD mutants (N501Y, L452R, K417T/E484K/N501Y) were purchased from Sino Biological Inc. (Beijing, China).
Monoclonal antibodies (mAbs)
The immune scheme for mAb production was described by us elsewhere26. Mice were kept on a 12-h light/12-h dark cycle, at 22–24 °C and 30–70% humidity, with ad libitum access to food and water. MAbs were prepared following standard hybridoma technology, as previously described60. Fusion was performed 2 weeks after the final immunization. The resulting hybridomas were screened for the secretion of SARS-CoV-2- and SARS-CoV-specific mAbs using a S-2P binding assay. Hybridoma cells were cloned using limiting dilution at least three times, and positive clones were expanded and cultured in 75-cm2 flasks. MAbs were prepared by injecting hybridoma cells into the peritoneal cavities of pristine-primed BALB/c mice; ascites was collected after 9–12 days and stored at −20 °C. MAbs were purified from mouse ascites using protein A agarose columns (GE Healthcare).
Expression and purification of IgG
The variable domain genes of CR3022 (ref. 23) and REGN10933 (ref. 32) heavy and light chains were inserted into a pTT5 (Thermo Fisher Scientific) vector containing the constant region of the human IgG. The recombinant antibodies were expressed in Chinese hamster ovary (CHO) cells through transient transfection and purified from culture media by affinity chromatography using MabSelect Sure resin (GE Healthcare).
Protein samples were mixed with loading buffer (50 mM Tris pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 0.01% bromophenol blue, 8% glycerol), boiled for 10 min, and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Equal amounts of protein for each sample were loaded onto SDS-PAGE gels. The proteins were electrophoresed for 70 min at 120 V in a BioRad MINI-PROTEAN Tetra system (BioRad Laboratories, CA, USA), and the gel was stained with Coomassie Brilliant Blue R-250 (Bio-Rad) for 30 min at room temperature.
Enzyme-linked immunosorbent assay
Purified proteins were coated into the wells of 96-well microtiter plates at 100 ng/well in PBS and incubated at 37 °C for 4 h. The background was blocked with 1× enzyme dilution buffer (PBS + 0.25% casein + 1% gelatin + 0.05% proclin-300) at 37 °C for 2 h. Antibodies or sera at 2 µg/mL or 1:100, respectively, was threefold serially diluted, added to the wells (100 µL), and incubated at 37 °C for 1 h. A horseradish peroxidase (HRP)-labeled goat anti-mouse or goat anti-human antibody (Abcam) was used as the secondary antibody at 1:5000 for 30 min. Wells were washed again and the reaction catalyzed using o-phenylenediamine substrate at 37 °C for 10 min. The OD450nm (reference, OD620nm) was measured on a microplate reader (TECAN, Männedorf, Switzerland) with a cut-off value of 0.1. The half-effective concentration (EC50) or half-effective titers (ET50) was calculated by sigmoid trend fitting using GraphPad Prism software (GraphPad Software, CA, USA).
SARS-CoV-2 neutralization assay
SARS-CoV-2 live virus focus reduction neutralization test (FRNT) was performed in a certified Biosafety level 3 laboratory, as previously described5. Neutralization assays against live SARS-CoV-2 were conducted using a clinical isolate (EPI_ISL_406594, WT, https://www.epicov.org/epi3/frontend#1903f; GWHBDSE01000000, B.1.351), previously obtained from a nasopharyngeal swab of an infected patient. Serial dilutions of tested antibodies were mixed with 50 μL of SARS-CoV-2 (100 focus forming units) in 96-well microwell plates and incubated at 37 °C for 1 h. Mixtures were then transferred to 96-well plates seeded with Vero E6 cells and allowed to absorb for 1 h at 37 °C. Inoculums were removed before adding the overlay media (100 μL MEM containing 1.6% carboxymethylcellulose). The plates were then incubated at 37 °C for 24 h. Overlays were removed and then cells were fixed with 4% paraformaldehyde solution for 30 min, and permeabilized with Perm/Wash buffer (BD Biosciences) containing 0.1% Triton X-100 for 10 min. Cells were incubated with rabbit anti-SARS-CoV-2 NP IgG (Sino Biological, Inc.) for 1 h at room temperature followed by HRP-conjugated goat anti-rabbit IgG (H + L) antibody (TransGen Biotech, Beijing). The reactions were developed with KPL TrueBlue Peroxidase substrates (Seracare Life Sciences Inc.). The numbers of SARS-CoV-2 foci were calculated using an EliSpot reader (Cellular Technology Ltd).
Pseudotype LV-based neutralization test
Antibodies were tested against lentiviral pseudotyping particles (LVpp) bearing the SARS-CoV-2 spike antigen based on H1299-ACE2hR cells, as described previously27. In briefly, SARS-CoV-2 LVpp were generated by co-transfection of a lentiviral packaging plasmid (psPAX2, Addgene), a SARS-CoV-2 spike expression plasmid (containing codon-optimized spike gene derived from the strain of MN908947.3 (WT) or EPI_ISL_601443 (B.1.1.7, https://www.epicov.org/epi3/frontend#2c197c) or EPI_ISL_700428 (B.1.351, https://www.epicov.org/epi3/frontend#31cdb6) or EPI_ISL_792680 (P.1, https://www.epicov.org/epi3/frontend#16776d) and a green fluorescent protein (mNeonGreen) reporter vector (pLvEF1α-mNG, carrying EF1α promoter-driven mNeonGreen expressing cassette) in 293 T cells. Infection and neutralization assays were performed on H1299-ACE2hR cells, which stably over-expressed human ACE2 (enabling it is highly susceptible to SARS-CoV-2 virus) and nuclear-localized RFP (H2B-mRuby3, allowing accurate cell counting) based on H1299 cells. For ppNAT tests, serially diluted antibodies were incubated with LVpp inoculum (0.5 TU/cell) for 1 h. Subsequently, the mixtures were incubated with the cells, which had been pre-seeded in 96-well cell culture plates with an optically clear bottom. After 36-h incubation, the plates were imaged by using Opera Phenix or Operetta CLS high-content equipment (PerkinElmer). For quantitative determination, fluorescence images were analyzed by Columbus Software 2.5.0 (PerkinElmer), the numbers of mNeonGreen (+) cells per well were calculated to indicate the infection performance, and the total cell numbers per well were also counted to normalize the readouts. The reduction (%) on mNeonGreen (+) cells of the plasma-treated well in comparison with control-well was calculated to show the neutralization activity. The ppNAT titer of each sample were expressed as the maximum dilution concentration required to achieve infection inhibition by 50% (IC50). The IC50 value was determined by the 4-parameter logistic (4PL) regression using GraphPad Prism v8.0.
Pseudotype VSV-based neutralization test
The VSV-based neutralization test was carried out as described28. The cultured supernatant of the monoclonal hybridoma cells and gradient-diluted purified antibodies were mixed with diluted VSV-SARS-CoV-2-Sdel18 virus (MOI = 0.05) and incubated at 37 °C for 1 h. All samples and viruses were diluted with 10% FBS-DMEM. The mixture was added to pre-seeded BHK21-hACE2 cells. After incubating for 12 h, fluorescence images were obtained with Opera Phenix or Operetta CLS equipment (PerkinElmer). For quantitative analysis, fluorescence images were analyzed using the Columbus system (PerkinElmer), and the numbers of GFP-positive cells for each well were counted to represent infection performance. The reduction (%) in the number of GFP-positive cells in mAb-treated wells compared with that in nontreated control wells were calculated to show the neutralizing potency.
All high-purity RBD, Fab, and immune complex proteins were subjected to HPLC (Waters; Milford, MA) analysis using a TSK Gel G5000PWXL7.8 × 300-mm column (TOSOH, Tokyo, Japan) equilibrated in PBS, pH 7.4. The system flow rate was maintained at 0.5 mL/min and eluted proteins were detected at 280 nm.
K D determination
KD values were determined by SPR technology using a Biacore 8K instrument (GE Healthcare). The S-2P or RBD was amine-coupled to a CM-5 sensor chip for use. Antibodies was then captured on the sensor surface at a flow rate of 30 μL/min in PBS-P + buffer (0.2 M phosphate buffer with 27 mM KCl, 1.37 M NaCl, and 0.5% Surfactant P20 (Tween 20)). The antibodies were tested using serially diluted concentrations (200, 150, 100, 75, 50, 37.5, 25, 18.75, 12.5, and 9.375 nM). The flow durations were 200 s for the association stage and 10 min for dissociation. Association rates (ka), dissociation rates (kd), and affinity constants (KD) were calculated using BIAcore evaluation software.
A competition assay was carried out to investigate the binding mode of the monoclonal antibodies with hACE2 (or between two antibodies) using SPR technology in a Biacore 8K instrument (GE healthcare). All experiments were performed at 25 °C, and the biosensors were pre-equilibrated in PBS-P + buffer (0.2 M phosphate buffer with 27 mM KCl, 1.37 M NaCl, and 0.5% Surfactant P20 [Tween 20]) for 10 min. Antibodies (first protein) at 3000 nM were loaded onto the biosensors for 500 s, followed by flow of the second interacting protein (hACE2 or the second antibody), also at 3000 nM for 500 s. The unblocked pattern of the RBD with buffer was used as a control.
Preparation, crystallization, and structure determination of immune complexes
7D6, 6D6, and 16D8 Fabs were prepared by papain digestion of the mAb and purified with Protein A (GE Healthcare). The SARS-CoV-2 RBD was mixed with each Fab in a 1:1.2 molar ratio and incubated at 37 °C for 2 h. The immune complex was further purified to remove any excess Fab by gel filtration on a Superdex 200 Increase column (GE Healthcare) in 10 mM Tris pH 8.0 with 50 mM NaCl. The complex was concentrated to ~7.5 mg/mL for crystallization.
The crystallization was performed using sitting-drop vapor diffusion in the screening stage and hanging drop in microseeding optimization at 20 °C. Crystals of the 7D6:RBD complex were grown in 0.2 M potassium dihydrogen phosphate with 20% PEG3350, whereas crystals of the 6D6:RBD complex were grown in 0.2 M sodium thiocyanate with 20% PEG3350. Crystal growth took about 7 days before final data collection. Crystals were cryo-protected in reservoir solution supplemented with 30% glycerol at 100 K before collection of the diffraction data. Diffraction data were collected at Shanghai Synchrotron Radiation Facility (SSRF) beamline BL17U1 using a DECTRIS EIGER X 16M Detector (wavelength, 0.97919 Å). The diffraction data were auto-processed with XDS software by aquarium pipeline61. The complex structures were determined by the molecular replacement method using Phaser62. The search model for RBD, 7D6 Fab, and 6D6 Fab phasing are COVID-19 RBD structure (PDB no. 6M0J: https://www.rcsb.org/structure/6M0J), Fab structure in PDB no. 6RCO, and Fab structure in PDB no. 1WEJ, respectively. The resulting models were manually built in COOT63, refined with PHENIX64 and analyzed with MolProbity65. In brief, one round of rigid-body refinement was performed after molecular replacement phasing. The refined models were manually modified in COOT; coordinates and individual B factors were refined in reciprocal space. TLS refinement was performed in the later stages with auto-searched TLS groups in PHENIX, which were listed in REMARK 3 sections in the deposited cif files. Data collection and structure refinement statistics are summarized in Table S3. All figures were prepared with PyMoL Molecular Graphics System (https://pymol.org).
Sequence and conservation analysis of epitopes
SARS-CoV-2 S gene mutations were calculated based on those within GISAID (https://www.gisaid.org) on 11 July 2021 (n = 2,216,094). SARS-CoV S genes were sourced from ViPR (https://www.viprbrc.org) and NCBI (https://www.ncbi.nlm.nih.gov) using only those deposited before December 2019 to exclude SARS-CoV-2 (search criteria: SARS-related coronavirus, full-length genomes, all host; n = 77, performed on 11 July 2021). Pangolin sequences were sourced from GISAID (n = 6). Reported for percent conservation are the number of sequences with an identical change at a position divided by the total number of sequences (include Sarbecovirus clade 1, 2, 3 (ref. 29)). The conservation figure indicating the sequence conservation was generated using PyMoL Molecular Graphics System.
Preparation and data collection of Cryo-EM samples
Aliquots (3 μL) of 0.5 mg/mL purified S-2P protein or its immune complexes were loaded onto glow-discharged (60 s at 20 mA) holey carbon Quantifoil grids (R1.2/1.3, 200 mesh, Quantifoil Micro Tools) using a Vitrobot Mark IV (Thermo Fisher Scientific) at 100% humidity and 4 °C. Data were acquired using the EPU software on an FEI Tecnai F30 transmission electron microscope (Thermo Fisher Scientific) operated at 300 kV and equipped with a Thermo Fisher Falcon-3 direct detector. Images were recorded in the 39-frame movie mode at a nominal magnification of 93,000× with a pixel size of 1.12 Å on the sample level and an underfocus range of 1.5–2.8 μm. The total electron dose was set to 30e− Å−2 and the exposure time was 1.0 s.
Cryo-EM data processing
Movie frame alignment and contrast transfer function estimation of each aligned micrograph were carried out with the programs of Motioncor66 and Gctf67. Particles were picked by the “Template picker” session of CryoSPARC v2 (ref. 68). Two rounds of reference-free 2D classification were performed, and well-defined particle images were selected.
Spike shedding assay
The spike shedding assay was performed as described by Yan et al.69. In brief, plasmids encoding SARS-CoV-2 wild-type S were transfected into HEK293T cells. Cells samples were prepared in multiples for serial incubation with IgG or Fabs (1 mg/mL) at 37 °C for 120, 60, and 5 min. Immediately after the incubation time, cells were transferred to ice then thoroughly washed with ice-cold PBS and 2% FBS. Samples were then stained with anti-mouse IgG (H + L) Alexa Flour 647 (Thermo Fisher) for 30 min. After thorough washes with ice-cold PBS and 2% FBS, samples were resuspended and analyzed with FACS Calibur (BD Biosciences, USA) and FlowJo 10 software (FlowJo, USA). Binding at each time point was determined by the percentage of positive cells in the selected gates and normalized correlated to that at the time point of 5 min (Fig. S5).
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
Burki, T. Understanding variants of SARS-CoV-2. Lancet 397, 462 (2021).
Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020).
Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).
Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020).
Thomas, K. & Kolata, G. President Trump Received Experimental Antibody Treatment. https://www.nytimes.com/2020/10/02/health/trump-antibody-treatment.html (2020).
Li, T., Zhang, T., Gu, Y., Li, S. & Xia, N. Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Res. 1, 139–150 (2021).
Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 1–9 (2021).
Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393.e12 (2021).
Wang P, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 29, 747–751.e4, https://doi.org/10.1016/j.chom.2021.04.007 (2021).
Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372–2383.e9 (2021).
Saphire, E. O. et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293, 1155–1159 (2001).
Laursen, N. S. et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 362, 598–602 (2018).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e278 (2020).
Matheson, N. J. & Lehner, P. J. How does SARS-CoV-2 cause COVID-19? Science 369, 510–511 (2020).
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727–11734 (2020).
Walls, A. C. et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell 176, 1026–1039.e1015 (2019).
Bruchez, A. et al. MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses. Science 370, 241 (2020).
Wells, A. I. & Coyne, C. B. Inhibiting Ebola virus and SARS-CoV-2 entry. Science 370, 167 (2020).
Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274–1278 (2020).
Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119–1123 (2020).
Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633 (2020).
Huo, J. et al. Neutralization of SARS-CoV-2 by destruction of the prefusion spike. Cell Host Microbe 28, 445–454.e446 (2020).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
Li, T. et al. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerging Microbes Infections 9, 2076–2090 (2020).
Chang, L. et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat. Commun. 12, 1383 (2021).
Xiong, H.-L. et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg. Microbes Infect. 9, 2105–2113 (2020).
Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97–102 (2021).
Mullen, J. L., Tsueng, G., Latif, A. A. & Alkuzweny, M. SARS-CoV-2 (hCoV-19) Mutation Reports. https://outbreak.info/situation-reports (2021).
Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 184, 4969–4980 (2021).
Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950–957 (2020).
Clark, S. A. et al. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 184, 2605–2617.e18 (2021).
Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473–1479 (2020).
Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828–842.e816 (2020).
Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat. commun. 11, 5413 (2020).
Kreye, J. et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 Hamster model. Cell 183, 1058–1069.e1019 (2020).
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e1021 (2020).
Bertoglio, F. et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell reports 36, 109433 (2021).
Shi, R. et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 584, 1–8 (2020).
Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013–1023.e1013 (2020).
Brouwer, P., Caniels, T. G., Straten, K., Snitselaar, J. L. & Gils, M. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643–650 (2020).
Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846–854 (2020).
Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. transl. med. 13, eabf1906 (2020).
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
Hanke, L. et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat. Commun. 11, 4420 (2020).
Custódio, T. F. et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat. Commun. 11, 5588 (2020).
Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479–1484 (2020).
Yao, H. et al. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Cell Res. 31, 25–36 (2021).
Zhang, C. et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat. Commun. 12, 264 (2021).
Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27, 950–958 (2020).
Wrapp, D. et al. Structural basis for potent neutralization of betacoronaviruses by single-domain Camelid antibodies. Cell 181, 1436–1441 (2020).
Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505–1509 (2020).
Liu, H. et al. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity 53, 1272–1280.e1275 (2020).
Zheng, Q. et al. Viral neutralization by antibody-imposed physical disruption. Proc. Natl Acad. Sci. USA 116, 26933–26940 (2019).
Bangaru, S. et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 177, 1136–1152.e1118 (2019).
Watanabe, A. et al. Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism. Cell 177, 1124–1135.e1116 (2019).
Shen, C. et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci. Transl. Med. 9, eaam5752 (2017).
Varecková, E. et al. Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J. Immunol. Methods 180, 107–116 (1995).
Yu, F. et al. Aquarium: an automatic data-processing and experiment information management system for biological macromolecular crystallography beamlines. J. Appl. Crystallogr. 52, 472–477 (2019).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2126–2132 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213–221 (2010).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 12–21 (2010).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331 (2017).
Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Yan, R. et al. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. 31, 517–525 (2021).
This work was supported by grants from the National Natural Science Foundation of China (grant nos. 82001756, 81991491 and U1705283), the National Key Research and Development Program of China (grant no. 2020YFC0842600), the Science and Technology Major Projects of Xiamen (grant no. 3502Z20203023). We thank Dr. Huan Zhou (beamline BL17U1 at the Shanghai Synchrotron Radiation Facility) for the assistance in X-ray data collection and processing. We would like to thank Guangdong Center for Human Pathogen Culture Collection (GDPCC) of China and Guangdong Provincial Center for Disease Control and Prevention of China for providing the authentic SARS-CoV-2 (B.351) for neutralization assay.
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, T., Xue, W., Zheng, Q. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat Commun 12, 5652 (2021). https://doi.org/10.1038/s41467-021-25997-3